Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by askretkaon Nov 12, 2022 7:04am
225 Views
Post# 35093384

RE:Onc Pela production cost & supply

RE:Onc Pela production cost & supply
I think Pelareorep will still require biohazard handling meaning the empty vials ot partial unused ir expired will have to go into yellow biohazard buckets which are commonplace and everywhere throughout hospitals. Chemo drugs or Cytotoxic drugs need to go into special red buckets as do all patient blood draw samples have to go into red Cytotoxic buckets. These new genetic altered viruses will need special precautions. Patients will require the patient to be isolated in their own room most likely and special trained staff costing the hospitals more $$ Pelareorep will be able to be used on regular chemo wards with 10 patients or more in same area and no new special training for staff being pretty cost effective for hospitals. Viruses can be tricky to manufacture but Matt did say in a podcast almost two years ago that they had no manufacturing problems and would be able to scale up when needed.
<< Previous
Bullboard Posts
Next >>